Controlled Trial of 3 4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)

Study Overview

The overall purpose is to provide children access to 3,4-DAP, which is not currently approved by the FDA for use in the United States.

Study Description

This study is designed to provide 3,4-DAP to patients with Lambert-Eaton Myasthenic Syndrome (LEMS) in attempt to improve their quality of life.

  • IRB Number: 1010002406
  • Research Study Identifier: TX1285
  • Principal Investigator: Robert Pascuzzi, MD

Recruitment Status

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.